Related references
Note: Only part of the references are listed.Identification of an AXL kinase inhibitor in triple-negative breast cancer by structure-based virtual screening and bioactivity test
Pei Li et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2022)
AXL Receptor Tyrosine Kinase as a Promising Therapeutic Target Directing Multiple Aspects of Cancer Progression and Metastasis
Marie-Anne Goyette et al.
CANCERS (2022)
A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy
Pavlos Msaouel et al.
SCIENCE TRANSLATIONAL MEDICINE (2022)
Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
Anna Adam-Artigues et al.
SCIENCE ADVANCES (2022)
Inhibitory effect of the novel tyrosine kinase inhibitor DCC-2036 on triple-negative breast cancer stem cells through AXL-KLF5 positive feedback loop
Yingying Shen et al.
CELL DEATH & DISEASE (2022)
miR-99a-5p modulates doxorubicin resistance via the COX-2/ABCG2 axis in triple-negative breast cancer: from the discovery to in vivo studies
Iris Garrido-Cano et al.
CANCER COMMUNICATIONS (2022)
MicroRNA-432 Acts as a Prognostic Biomarker and an Inhibitor of Cell Proliferation, Migration, and Invasion in Breast Cancer
Jianhua Wu et al.
CLINICAL BREAST CANCER (2021)
MicroRNA 34a-AXL Axis Regulates Vasculogenic Mimicry Formation in Breast Cancer Cells
Dansaem Lim et al.
GENES (2021)
Inhibition of the Axl pathway impairs breast and prostate cancer metastasis to the bones and bone remodeling
Mai Tanaka et al.
CLINICAL & EXPERIMENTAL METASTASIS (2021)
Immune Evasion Mechanism and AXL
Hye-Youn Son et al.
FRONTIERS IN ONCOLOGY (2021)
lncRNA GSEC Promotes the Progression of Triple Negative Breast Cancer (TNBC) by Targeting the miR-202-5p/AXL Axis
Jianhua Zhang et al.
ONCOTARGETS AND THERAPY (2021)
The Role of the Receptor Tyrosine Kinase Axl in Carcinogenesis and Development of Therapeutic Resistance: An Overview of Molecular Mechanisms and Future Applications
Martha Wium et al.
CANCERS (2021)
The AXL-PYK2-PKCα axis as a nexus of stemness circuits in TNBC
Lohit Khera et al.
LIFE SCIENCE ALLIANCE (2021)
Anti-Axl monoclonal antibodies attenuate the migration of MDA-MB-231 breast cancer cells
Hong Chang et al.
ONCOLOGY LETTERS (2021)
AXL Overexpression in Tumor-Derived Endothelial Cells Promotes Vessel Metastasis in Patients With Hepatocellular Carcinoma
Zong-Tao Chai et al.
FRONTIERS IN ONCOLOGY (2021)
Cancer stem cell-targeted therapeutic approaches for overcoming trastuzumabresistance in HER2-positive breast cancer
Yan Qiu et al.
STEM CELLS (2021)
Soluble AXL as a marker of disease progression and survival in melanoma
Karine Flem-Karlsen et al.
PLOS ONE (2020)
AXL as a Target in Breast Cancer Therapy
Sierra A. Colavito
JOURNAL OF ONCOLOGY (2020)
Synergistic Induction of Apoptosis by the Combination of an Axl Inhibitor and Auranofin in Human Breast Cancer Cells
Yeon-Sang Ryu et al.
BIOMOLECULES & THERAPEUTICS (2020)
The crosstalk between AXL and YAP promotes tumor progression through STAT3 activation in head and neck squamous cell carcinoma
Jiayi Li et al.
CANCER SCIENCE (2020)
Gas6 expression is reduced in advanced breast cancers
Ayman M. Ibrahim et al.
NPJ PRECISION ONCOLOGY (2020)
AXL confers cell migration and invasion by hijacking a PEAK1-regulated focal adhesion protein network
Afnan Abu-Thuraia et al.
NATURE COMMUNICATIONS (2020)
MiRNA and LncRNA as Potential Biomarkers in Triple-Negative Breast Cancer: A Review
Simona Ruxandra Volovat et al.
FRONTIERS IN ONCOLOGY (2020)
AXL Receptor in Breast Cancer: Molecular Involvement and Therapeutic Limitations
Italia Falcone et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Axl-148b chimeric aptamers inhibit breast cancer and melanoma progression
Lorena Quirico et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2020)
Cabozantinib-related cardiotoxicity: a prospective analysis in a real-world cohort of metastatic renal cell carcinoma patients
Roberto Iacovelli et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Pan-TAM Tyrosine Kinase Inhibitor BMS-777607 Enhances Anti-PD-1 mAb Efficacy in a Murine Model of Triple-Negative Breast Cancer
Canan Kasikara et al.
CANCER RESEARCH (2019)
Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance
Melissa Dolan et al.
PLOS ONE (2019)
AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications
Chenjing Zhu et al.
MOLECULAR CANCER (2019)
Phase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Non-Small-Cell Lung Cancer
Hiroshi Nokihara et al.
CLINICAL LUNG CANCER (2019)
Management of Medullary Thyroid Cancer
David Viola et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2019)
Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET
Yingying Shen et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Targeting of TAM Receptors Ameliorates Fibrotic Mechanisms in Idiopathic Pulmonary Fibrosis
Milena S. Espindola et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
ARL2 overexpression inhibits glioma proliferation and tumorigenicity via down-regulating AXL
Yulin Wang et al.
BMC CANCER (2018)
A novel AXL chimeric antigen receptor endows T cells with anti-tumor effects against triple negative breast cancers
Jing Wei et al.
CELLULAR IMMUNOLOGY (2018)
A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers
Aflah Roohullah et al.
INVESTIGATIONAL NEW DRUGS (2018)
Comprehensive Characterization of Cancer Driver Genes and Mutations (vol 173, 371.e1, 2018)
Matthew H. Bailey et al.
CELL (2018)
The HSP90 Family: Structure, Regulation, Function, and Implications in Health and Disease
Abdullah Hoter et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
An integrated approach of bioinformatic prediction and in vitro analysis identified that miR-34a targets MET and AXL in triple-negative breast cancer
Shadan Hajalirezay Yazdi et al.
CELLULAR & MOLECULAR BIOLOGY LETTERS (2018)
Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis
Wilhem Leconet et al.
CLINICAL CANCER RESEARCH (2017)
Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients
Sara M. Tolaney et al.
ONCOLOGIST (2017)
Expression of Axl and its prognostic significance in human breast cancer
Gaoyuan Jin et al.
ONCOLOGY LETTERS (2017)
Phosphatidylserine Sensing by TAM Receptors Regulates AKT-Dependent Chemoresistance and PD-L1 Expression
Canan Kasikara et al.
MOLECULAR CANCER RESEARCH (2017)
Axl inhibition induces the antitumor immune response which can be further potentiated by PD-1 blockade in the mouse cancer models
Zhiqiang Guo et al.
ONCOTARGET (2017)
Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity
Stanley G. Kimani et al.
SCIENTIFIC REPORTS (2017)
Giving AXL the axe: targeting AXL in human malignancy
Carl M. Gay et al.
BRITISH JOURNAL OF CANCER (2017)
Negative feedback regulation of AXL by miR-34a modulates apoptosis in lung cancer cells
Chun-Yu Cho et al.
RNA (2016)
Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma
Parag P. Patwardhan et al.
ONCOTARGET (2016)
Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer
Daniel Rayson et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
被撤回的出版物: Dicer Elicits Paclitaxel Chemosensitization and Suppresses Cancer Stemness in Breast Cancer by Repressing AXL (Retracted article. See vol. 78, pg. 5719, 2018)
Ting-Yu Chang et al.
CANCER RESEARCH (2016)
Impact of Expression of Vimentin and Axl in Breast Cancer
Kimihiro Tanaka et al.
CLINICAL BREAST CANCER (2016)
Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy
Maurizio Scaltriti et al.
CLINICAL CANCER RESEARCH (2016)
miR-135b, upregulated in breast cancer, promotes cell growth and disrupts the cell cycle by regulating LATS2
Kaiyao Hua et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
Protein kinase C α is involved in the regulation of AXL receptor tyrosine kinase expression in triple-negative breast cancer cells
Chia-Herng Yue et al.
MOLECULAR MEDICINE REPORTS (2016)
Reprogramming the immunological microenvironment through radiation and targeting Axl
Todd A. Aguilera et al.
NATURE COMMUNICATIONS (2016)
Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance
Miles A. Miller et al.
CANCER DISCOVERY (2016)
Suppression of the metastatic spread of breast cancer by DN10764 (AZD7762)-mediated inhibition of AXL signaling
Joon-Suk Park et al.
ONCOTARGET (2016)
AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients
Giulia Bottai et al.
NPJ BREAST CANCER (2016)
Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth
Francesca Zanconato et al.
NATURE CELL BIOLOGY (2015)
Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways
Xinyan Wu et al.
ONCOTARGET (2015)
Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors
Hagop M. Kantarjian et al.
BLOOD (2014)
Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells
Kinga Penzes et al.
CANCER BIOLOGY & THERAPY (2014)
Yes-associated protein 1 (YAP1) promotes human gallbladder tumor growth via activation of the AXL/MAPK pathway
Maolan Li et al.
CANCER LETTERS (2014)
AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs
Catherine Wilson et al.
CANCER RESEARCH (2014)
The receptor tyrosine kinase Axl in cancer: Biological functions and therapeutic implications
Juliano D. Paccez et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
An AXL/LRP-1/RANBP9 complex mediates DC efferocytosis and antigen cross-presentation in vivo
Manikandan Subramanian et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Axl receptor tyrosine kinase expression in breast cancer
Timothy M. D'Alfonso et al.
JOURNAL OF CLINICAL PATHOLOGY (2014)
The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells
Magdalena Paolino et al.
NATURE (2014)
AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells
M. K. Asiedu et al.
ONCOGENE (2014)
Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy
W. Leconet et al.
ONCOGENE (2014)
AXL kinase as a novel target for cancer therapy
Xiaoliang Wu et al.
ONCOTARGET (2014)
Axl as a mediator of cellular growth and survival
Haley Axelrod et al.
ONCOTARGET (2014)
Activation of HER3 Interferes with Antitumor Effects of Axl Receptor Tyrosine Kinase Inhibitors: Suggestion of Combination Therapy
Robert Torka et al.
NEOPLASIA (2014)
TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase
Xiaoping Wang et al.
CANCER RESEARCH (2013)
An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
Lauren Averett Byers et al.
CLINICAL CANCER RESEARCH (2013)
Axl/Gas6 pathway positively regulates FLT3 activation in human natural killer cell development
Il-Kyoo Park et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2013)
Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial
David C. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents
Sharad Sharma et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays
T. S. Gujral et al.
ONCOGENE (2013)
The Receptor AXL Diversifies EGFR Signaling and Limits the Response to EGFR-Targeted Inhibitors in Triple-Negative Breast Cancer Cells
Aaron S. Meyer et al.
SCIENCE SIGNALING (2013)
Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy
M. Campone et al.
ANNALS OF ONCOLOGY (2012)
Macrophage-tumor crosstalk: role of TAMR tyrosine kinase receptors and of their ligands
Thomas Schmidt et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2012)
Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation
Yao Dai et al.
CLINICAL & EXPERIMENTAL METASTASIS (2012)
Systematic Identification of the HSP90 Candidate Regulated Proteome
Zhixiang Wu et al.
MOLECULAR & CELLULAR PROTEOMICS (2012)
The Chk1 inhibitor AZD7762 sensitises p53 mutant breast cancer cells to radiation in vitro and in vivo
Zhikun Ma et al.
MOLECULAR MEDICINE REPORTS (2012)
Targeting Axl With an High-affinity Inhibitory Aptamer
Laura Cerchia et al.
MOLECULAR THERAPY (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
Christina Curtis et al.
NATURE (2012)
Fra-1 controls motility of bladder cancer cells via transcriptional upregulation of the receptor tyrosine kinase AXL
A. E. Sayan et al.
ONCOGENE (2012)
Axl glycosylation mediates tumor cell proliferation, invasion and lymphatic metastasis in murine hepatocellular carcinoma
Ji Li et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2012)
Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA
Mark Mackiewicz et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Control of mammary tumor differentiation by SKI-606 (bosutinib)
L. Hebbard et al.
ONCOGENE (2011)
AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma
M. Z. Xu et al.
ONCOGENE (2011)
Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer
K. Vuoriluoto et al.
ONCOGENE (2011)
Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer
G. Mudduluru et al.
ONCOGENE (2011)
BMS-777607, a Small-Molecule Met Kinase Inhibitor, Suppresses Hepatocyte Growth Factor-Stimulated Prostate Cancer Metastatic Phenotype In vitro
Yao Dai et al.
MOLECULAR CANCER THERAPEUTICS (2010)
An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies
X. Ye et al.
ONCOGENE (2010)
Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival
Christine Gjerdrum et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases
Fawn Qian et al.
CANCER RESEARCH (2009)
Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL
Li Liu et al.
CANCER RESEARCH (2009)
Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis
Y. Li et al.
ONCOGENE (2009)
AXL is a potential target for therapeutic intervention in breast cancer progression
Yi-Xiang Zhang et al.
CANCER RESEARCH (2008)
Rac Activation and Inactivation Control Plasticity of Tumor Cell Movement
Victoria Sanz-Moreno et al.
CELL (2008)
SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells
Adina Vultur et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Axl and Tyro3 Modulate Female Reproduction by Influencing Gonadotropin-Releasing Hormone Neuron Survival and Migration
Angela Pierce et al.
MOLECULAR ENDOCRINOLOGY (2008)
Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-κB and Brg-1
K-Y Tai et al.
ONCOGENE (2008)
Macrophages and dendritic cells use different Axl/Mertk/Tyro3 receptors in clearance of apoptotic cells
Heather M. Seitz et al.
JOURNAL OF IMMUNOLOGY (2007)
Twist mediates suppression of inflammation by type IIFNs and Axl
M. Nusrat Sharif et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases
Sassan Hafizi et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2006)
被撤回的出版物: Soluble Axl is generated by ADAM10-dependent cleavage and associates with Gas6 in mouse serum (Retracted article. See vol. 31, pg. 1330, 2011)
V Budagian et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Effects of Gash and hydrogen peroxide in Axl ubiquitination and downregulation
P Valverde
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Gas6 receptors Axl, Sky and Mer enhance platelet activation and regulate thrombotic responses
WR Gould et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Inhibition of vascular endothelial growth factor receptor 2-mediated endothelial cell activation by Axl tyrosine kinase receptor
M Gallicchio et al.
BLOOD (2005)
Escape from Cbl-mediated downregulation: A recurrent theme for oncogenic deregulation of receptor tyrosine kinases
P Peschard et al.
CANCER CELL (2003)
Crystal structure of a C-terminal fragment of growth arrest-specific protein Gas6 -: Receptor tyrosine kinase activation by laminin G-like domains
T Sasaki et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Gas6 anti-apoptotic signaling requires NF-κB activation
F Demarchi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Structure of the C-terminal laminin G-like domain pair of the laminin α2 chain harbouring binding sites for α-dystroglycan and heparin
D Tisi et al.
EMBO JOURNAL (2000)
Share Paper
